logo
Why You'll See More Face Masks on Flights This Spring—and If You Should Be Wearing 1 Too, According to Doctors

Why You'll See More Face Masks on Flights This Spring—and If You Should Be Wearing 1 Too, According to Doctors

As frequent travelers, the Travel + Leisure team spends a lot of time in airports and on flights. Needless to say, we're uniquely attuned to travel trends, whether it's popular travel outfits or trending luggage. Recently, we've noticed a trend that's worthy of a little extra attention: masking.
The CDC recommends wearing masks when respiratory viruses are going around your community or if you're at risk for severe illness. On recent flights, we've noticed plenty of travelers masking up, and with the rise of reported cases of measles, whooping cough, and even tuberculosis, it begs the question: Are we at increased risk of contracting an illness while traveling, and should we be masking up on flights? I asked two medical experts to weigh in.
According to Dr. John Dooley, MD, most healthy individuals don't need to mask up during travel, although there are still risks. 'I don't routinely recommend people wear masks on airplanes, but I have no objection whatsoever if it helps to lessen one's likelihood of picking up a respiratory infection,' Dr. Dooley told me. He adds that if someone on your flight is sick and coughing, there's a 'not insignificant chance' that they'll pass that illness onto others nearby, so masking can provide peace of mind.
Plus, Dr. Dooley adds that 'most respiratory infection transmission does not occur on airplanes.' You're more likely to be exposed once you reach your destination—at a restaurant, museum, or large gathering, for example.
Dr. Ken Perry, MD, adds that masks may not be as effective as once thought, although they still provide increased protection. Needless to say, it's probably a good idea for vulnerable individuals to mask up. According to Dr. Dooley, for these patients, 'it makes good sense to take the precaution of wearing a mask, however imperfect the degree of protection.'
Dr. Perry agrees that extra precautions should be taken for the immunocompromised. He adds that this group includes patients who have had organ transplants and those who are undergoing chemotherapy, since these patients are 'far more likely to be susceptible to any communicable disease.'
However, both doctors push back at the idea of taking extra precautions due to reported cases of measles, whooping cough, and tuberculosis. They agree that the risk is low. Nonetheless, travelers can learn more about the health risks associated with various destinations by using the United States Centers for Disease Control and Prevention (CDC)'s travel information guide as a resource.
At the end of the day, masks can provide peace of mind during travel. Dr. Perry tells me travel decreases stress and increases beneficial neurotransmitters in the brain. 'The reality is that if a mask allows someone to take a vacation when they would otherwise stay at home, then it is a means to a very beneficial end.'
If you're in the market for a mask, whether you're immunocompromised, an anxious traveler, or you just always happen to sit next to a coughing passenger, we've found a CDC-approved mask at Amazon.
While there are plenty of counterfeit masks available at Amazon, these N95 masks are approved by the National Institute for Occupational Safety and Health (NIOSH), a research agency under the CDC. This mask is designed to block 95 percent of airborne particles, and one reviewer writes, 'It's comfortable enough I forget I'm wearing it sometimes.'
According to Dr. Perry, masks may be 'more beneficial for the harmful contaminants in the air rather than preventing viral infections.' Consider this mask not just for air travel, but also for visiting highly polluted destinations.
In addition to wearing a mask, you can also protect your health during travel by using hand sanitizer and disinfectant wipes. Keep reading for more travel essentials at Amazon under $30.
Love a great deal? Sign up for our T+L Recommends newsletter and we'll send you our favorite travel products each week.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

UnitedHealth Stock Is Having Its Worst Year Since 2008. Can It Recover?
UnitedHealth Stock Is Having Its Worst Year Since 2008. Can It Recover?

Yahoo

time2 minutes ago

  • Yahoo

UnitedHealth Stock Is Having Its Worst Year Since 2008. Can It Recover?

Key Points It isn't typical for UnitedHealth stock to finish a year lower than it started, let alone be down more than 40% as it is right now. Rising costs and uncertainty around healthcare reform are just a couple of the issues plaguing the stock. It's trading around multiyear lows, however, and is arguably a cheap buy. 10 stocks we like better than UnitedHealth Group › For years UnitedHealth Group (NYSE: UNH) has normally been a reliable dividend stock. But an abysmal start to 2025 has wiped out many of the gains that investors have achieved in recent years, with its five-year return now in negative territory. Year to date, the stock has fallen by nearly 45%, which is by no means normal for the healthcare stock. In fact, this is the worst it has performed since the Great Recession, when it tumbled by more than 54% in 2008. The big questions many investors are likely asking today are: Can it recover? Or is there more of a downfall to come for this once seemingly unstoppable stock? Big declines aren't the norm for UnitedHealth The past few years haven't been all that great for UnitedHealth, but by and large, this has been a fairly strong stock to own. It has typically outperformed the market. And outside of 2024 -- when it was down 4% -- the last time it finished a year in the red was (as noted) back in 2008, when the U.S. economy was in the midst of the Great Recession and the stock lost more than half of its value. Not only has UnitedHealth normally been a safe stock, it's also been a tremendous growth stock. Consider that if you invested $10,000 into its shares at the end of 2003, then 20 years later your investment would have been worth $181,000. But if you hung on until now, that investment would have fallen to a value of $101,000. While that's still a good return, it spotlights just how significant the decline has been this year, for a stock that's typically known for being a solid long-term investment. Still, the past doesn't predict the future. Why the company might face a tough road ahead The problem with UnitedHealth right now is that it's facing many challenges. Medical costs are up, and there's a lot of uncertainty in healthcare as the federal government looks to cut costs. Meanwhile, the Department of Justice is reportedly looking into UnitedHealth's billing practices. The danger is that the company may face financial repercussions and other headwinds, such as having to change its practices -- or at the very least, incurring higher-than-typical costs due to greater utilization rates. The latter, however, may be a shorter-term trend. Either way, this is a business known for consistently growing its operations, and that may not be a sure thing anymore. While UnitedHealth generated a healthy profit of more than $14.4 billion on revenue of $400.3 billion in 2024, investor concerns about long-term growth appear to be weighing on the stock. In May, the company suspended its outlook for the year; it also announced a change in CEO, with Andrew Witty stepping down for personal reasons and former CEO Stephen Hemsley taking over. Should you buy UnitedHealth stock today? While UnitedHealth stock has done well in previous years, that doesn't mean that it's a surefire bet to rebound soon. The good news is that it still has solid fundamentals. Since it's a key health insurer in the U.S., I'd be hesitant to count it out in the long run. There's some near-term risk and even some long-term uncertainty about how all the changes in the healthcare industry might pan out. But the stock is trading at levels it hasn't been at since 2020, and its valuation is just 12 times its trailing earnings. I think that gives it a good enough margin of safety at its current price, and that buying it today might prove to be a solid move. As long as you're willing to be patient, this can be a good stock to buy and hold. Should you buy stock in UnitedHealth Group right now? Before you buy stock in UnitedHealth Group, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and UnitedHealth Group wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $636,628!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,063,471!* Now, it's worth noting Stock Advisor's total average return is 1,041% — a market-crushing outperformance compared to 183% for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of July 28, 2025 David Jagielski has no position in any of the stocks mentioned. The Motley Fool recommends UnitedHealth Group. The Motley Fool has a disclosure policy. UnitedHealth Stock Is Having Its Worst Year Since 2008. Can It Recover? was originally published by The Motley Fool Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

Elon Musk's company just promised to save Nashville's traffic problems. We've heard this story before
Elon Musk's company just promised to save Nashville's traffic problems. We've heard this story before

CNN

time4 minutes ago

  • CNN

Elon Musk's company just promised to save Nashville's traffic problems. We've heard this story before

Aviation newsFacebookTweetLink Follow Nashville officials on Monday announced a massive public transportation partnership with Elon Musk's The Boring Company to alleviate the city's significant traffic congestion problems for travelers bound to the airport. But Musk has previously made many similar promises in a host of other American cities with little to show for it. At an announcement in Nashville, Gov. Bill Lee said the tunnel will be known as the 'Music City Loop' and that the project is '100% privately funded, there will be no cost to Tennessee taxpayers.' Lee did not detail who the funders are or the expected cost. The system aims to be the second such 'loop' by Musk's Boring Company, which currently operates an underground tunnel system in Las Vegas, where Tesla cars ferry people around and near the city's convention center. Lee said that a trip through the tunnel system will take eight to 10 minutes and that the plan is to complete the project within two years. The trip between the airport and downtown Nashville takes roughly 20 minutes on the road without traffic, according to Google Maps. But officials say traffic congestion in the city, especially around the airport, has been increasing. Construction will begin immediately following the approvals process, Lee's office said in a statement, and the first part of the operation is expected to open next year. Even at the announcement, there seemed to be some surprise at the proposed speed of the project. 'I know our engineering team was looking down — two years!' said Doug Kreulen, CEO of the Metropolitan Nashville Airport Authority, in a tone that seemed to mock supposed shock from the engineers. The Boring Company's president, Steve Davis, who also helped lead the Department of Government Efficiency, said during the announcement that they chose Nashville because they wanted to build where 'the system had to be useful and the community had to be welcoming.' Secretary of Transportation Sean Duffy also attended the event and spoke. But Musk, who has distanced himself from the Trump administration after leading DOGE, was not mentioned, and Musk did not promote Monday's announcement on X, his social media platform. Musk's xAI has also invested in Tennessee, setting up its supercomputer campuses in Memphis last year. Musk's AI company has also made some charitable overtures in the area, helping Memphis-Shelby County Schools with HVAC upgrades and other needs, as well as clearing some roads near schools and homes, the company said this month. Last week, Musk also announced his foundation donated $350,000 to the Boys and Girls Club of Greater Memphis to help cover funding gaps after losing government COVID pandemic era funds. Between 2017 and 2021, The Boring Company canceled or postponed similar projects in Chicago; Fort Lauderdale, Florida; the California cities of Los Angeles, San Bernardino and San Jose; and one from Baltimore to Washington, DC. The Boring Company has had a rocky existence ever since Musk first posted in 2016 that traffic was driving him 'nuts' and that he was going to 'build a tunnel boring machine and just start digging.' The Boring Company completed a test tunnel for regular electric vehicles in Los Angeles in 2018, but Musk said his ultimate vision included a 'hyperloop,' a low-pressure tube through which specially designed capsules would whisk passengers between cities at hundreds of miles per hour. Musk posted in 2017 that he had 'verbal government approval' to build a hyperloop between New York and Washington, DC. But it was unclear what official could give such an approval, given the dozens — if not hundreds — of municipalities and organizations that would be involved in such a project. By 2021, a proposed Baltimore-to-Washington segment evaporated from the company's website, though the company continues to tout the hyperloop idea without any specific plans or projects. Musk's smaller-scale vision, which he simply dubbed 'Loop,' continued to inch along, however — if not with similar themes of grand ideas and scaled-back realities. In April 2017, Musk presented an animated video at a Ted Ideas conference showing vehicles lowered into tunnels by elevators that seamlessly blended into curbside parking spots, with the vehicles then being whisked away on electric sleds. The Loop that has been built is also quite different than the Loop that was envisioned. The first segment, under the Las Vegas Convention Center, was completed in 2021, but instead of city denizens flitting across the city, convention-goers are simply driven by humans in normal Teslas through a fairly standard road tunnel. The Boring Company has since completed five more stations — for a total of eight — and the company says that 'Clark County and the City of Las Vegas have approved 68 miles of tunnel and 104 stations.' Musk's tunnels have had an even harder time spreading outside of Las Vegas. While multiple projects have been announced – most recently in Dubai in February 2025 – few have moved beyond the initial fanfare. Projects in Los Angeles, Chicago, and Baltimore all appear to have been quietly dropped, and despite an announcement for a Fort Lauderdale tunnel in 2021, the project appears to be suspended. In 2025, Fort Lauderdale Mayor Dean Trantalis told the South Florida Sun-Sentinel that the city needed to 'to see if they're still interested in fully funding the project as they had originally proposed.'

Bristol Myers Squibb and Bain Capital Create New Company Dedicated to Developing Innovative Immunology Therapies that Address the Unmet Medical Needs of Patients
Bristol Myers Squibb and Bain Capital Create New Company Dedicated to Developing Innovative Immunology Therapies that Address the Unmet Medical Needs of Patients

Yahoo

time8 minutes ago

  • Yahoo

Bristol Myers Squibb and Bain Capital Create New Company Dedicated to Developing Innovative Immunology Therapies that Address the Unmet Medical Needs of Patients

Five immunology assets in-licensed from BMS with potential to address unmet needs for patients with autoimmune diseases, including late-stage asset for lupus Bain Capital leads $300 million financing commitment PRINCETON, N.J. & BOSTON, July 28, 2025--(BUSINESS WIRE)--Bristol Myers Squibb (NYSE: BMY, "BMS") and Bain Capital today announced the creation of a new independent biopharmaceutical company ("NewCo") focused on developing new therapies for autoimmune diseases that address significant unmet needs of patients. The newly formed company launches with five immunology assets in-licensed from BMS and a $300 million financing commitment that was led by Bain Capital. The NewCo has a broad pipeline consisting of three clinical-stage and two Phase 1-ready investigational medicines that each target promising mechanisms in autoimmune diseases. The most advanced assets in the NewCo's portfolio are afimetoran, an oral, potential best-in-class TLR7/8 inhibitor that is currently being studied in a Phase 2 clinical trial for systemic lupus erythematosus (SLE), and BMS-986322, an oral TYK2 inhibitor, which successfully established proof-of-concept in a positive plaque psoriasis Phase 2 trial. Other licensed assets include BMS-986326, a novel, potential best-in-class, IL2 fusion protein that is currently being studied in Phase 1 clinical trials for SLE and atopic dermatitis, and BMS-986481 and BMS-986498, two Phase 1-ready biologics targeting the IL18 and IL10 pathways respectively. The assets licensed to NewCo reflect the strength of BMS's scientific innovation and hold promise to address unmet needs for patients with autoimmune diseases. As part of the agreement, BMS will retain a nearly 20 percent equity stake in NewCo and will be entitled to royalties and milestones tied to the success of each asset. Robert Plenge, MD, PhD, Executive Vice President and Chief Research Officer at BMS, will also serve on NewCo's Board of Directors. This transaction reflects BMS's strategic shift in Immunology research to focus on assets that have the potential to reset the immune system and promote tissue repair. It also further demonstrates the company's sharpened strategy to invest in areas where BMS is best positioned to lead, while enabling the continued development of promising medicines. "These assets have significant potential, and we are confident that this new company will drive their development to ensure greater impact for patients," said Julie Rozenblyum, Senior Vice President, Business Development at BMS. "Bain Capital's exceptional track record in building successful life science companies by providing focused development and dedicated resources makes them ideally suited to advance these assets to realize their full promise." Daniel S. Lynch will serve as the Executive Chairman of the Company's Board of Directors and interim CEO. Mr. Lynch is an accomplished biopharmaceutical industry leader with decades of strategic, management and operational experience at companies spanning many stages of growth. Nicholas Downing, MD, Adam M. Koppel, MD, PhD, and Andrew Kaplan from Bain Capital will also join Mr. Lynch and Dr. Plenge of BMS on NewCo's Board of Directors. "We are excited to partner with BMS and we share their commitment to improving lives through science," said Adam Koppel, a Partner at Bain Capital Life Sciences. "We look forward to working together and leveraging our company creation experience to build out this new platform and advance these distinct assets in an effort to bring innovative, high-quality therapies to patients with autoimmune diseases." "This is a unique opportunity to build an innovative biotech company with a strong scientific foundation and differentiated development capabilities," said Mr. Lynch. "I'm thrilled to have the opportunity to leverage my background and experience to contribute to the success of the company as it seeks to develop much-needed new therapies, and I look forward to supporting BMS and Bain Capital in the build-out of the company's operations." Bain Capital is investing in NewCo through its Life Sciences and Private Equity teams, drawing on over 40 years of supporting the growth and innovation of healthcare companies globally. Canada Pension Plan Investment Board also joined the investment. About Bristol Myers Squibb: Transforming Patients' Lives Through ScienceAt Bristol Myers Squibb, our mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases. We are pursuing bold science to define what's possible for the future of medicine and the patients we serve. For more information, visit us at and follow us on LinkedIn, X, YouTube, Facebook and Instagram. Bristol Myers Squibb Cautionary Statement Regarding Forward-Looking StatementsThis press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 regarding, among other things, the research, development and commercialization of pharmaceutical products, the creation of NewCo and the agreement with NewCo. All statements that are not statements of historical facts are, or may be deemed to be, forward-looking statements. Such forward-looking statements are based on current expectations and projections about our future financial results, goals, plans and objectives and involve inherent risks, assumptions and uncertainties, including internal or external factors that could delay, divert or change any of them in the next several years, that are difficult to predict, may be beyond our control and could cause our future financial results, goals, plans and objectives to differ materially from those expressed in, or implied by, the statements. These risks, assumptions, uncertainties and other factors include, among others, that the expected benefits of, and opportunities related to, the creation of NewCo and the agreement with NewCo may not be realized by Bristol Myers Squibb or may take longer to realize than anticipated, that the assets described in this press release, may not achieve their primary study endpoints or receive regulatory approval for the indications described in this release in the currently anticipated timeline or at all and, if approved, whether such assets will be commercially successful. No forward-looking statement can be guaranteed. Forward-looking statements in this press release should be evaluated together with the many risks and uncertainties that affect Bristol Myers Squibb's business and market, particularly those identified in the cautionary statement and risk factors discussion in Bristol Myers Squibb's Annual Report on Form 10-K for the year ended December 31, 2024, as updated by our subsequent Quarterly Reports on Form 10-Q, Current Reports on Form 8-K and other filings with the Securities and Exchange Commission. The forward-looking statements included in this document are made only as of the date of this document and except as otherwise required by applicable law, Bristol Myers Squibb undertakes no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events, changed circumstances or otherwise. About Bain CapitalFounded in 1984, Bain Capital is one of the world's leading private investment firms. We are committed to creating lasting impact for our investors, teams, businesses, and the communities in which we live. As a private partnership, we lead with conviction and a culture of collaboration, advantages that enable us to innovate investment approaches, unlock opportunities, and create exceptional outcomes. Our global platform invests across five focus areas: Private Equity, Growth & Venture, Capital Solutions, Credit & Capital Markets, and Real Assets. In these focus areas, we bring deep sector expertise and wide-ranging capabilities. We have 24 offices on four continents, more than 1,850 employees, and approximately $185 billion in assets under management. To learn more, visit Follow @BainCapital on LinkedIn and X (Twitter). corporatefinancial-news View source version on Contacts Bristol Myers Squibb Media Inquiries: media@ Investors: Bain Capital Scott Lessne / Charlyn LuskStantonslessne@ / clusk@ (646) 502-3569 / (646) 502-3549 Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store